Entry inhibitors
Inhibitors of viral attachment
The lectin cyanovirin-N (CV-N)
has initially been discovered as an active compound against HIV and was then
shown to present antiviral activity against other enveloped viruses (98, 99). This
antiviral activity results from interactions between CV-N and high-mannose
oligosaccharides on viral envelope glycoproteins (100). HCV envelope
glycoproteins are highly glycosylated and contain oligomannose glycans. It has
been shown that these oligomannose glycans interact with CV-N resulting in HCV
antiviral activity by blocking HCV entry into target cell (101). As most of
the HCV glycosylation sites are highly conserved, drugs that target glycans on
HCV glycoproteins may not lead so rapidly viral escape/resistance as it is the
case for HIV (92). Other
carbohydrate-binding agents, such as plant lectins, monoclonal antibodies and
the mannose-specific non-peptidic antibiotic Pradimicin A have been shown to
prevent HIV infectivity (102). Such
substances might also be efficient against other viruses that require a
glycosylated envelope for entry into target cells.
Another approach to target HCV
attachment might be the development of heparin-derived molecules, as heparin
has been shown to potently inhibit HCV E2, HCVpp, HCV-LP as well as HCVcc binding
to hepatoma cells (32, 35, 53,
103). The
systematic generation and screening of heparan sulfate-like molecules and
semisynthetic derivatives is already explored as an antiviral approach against
dengue virus infection (104).
Inhibitors of post binding
steps
Antiviral compounds targeting
viral entry may either act on conserved mechanisms or target specific cell
surface molecules. Recent studies have shown that long phosphorothioate
oligonucleotides (PS-ON), that are amphipathic DNA polymers, displays a sequence
independent antiviral activity against HIV by blocking virus-cell fusion (105). Most
recently, it could be demonstrated that PS-ON inhibit HCV fusion and entry (Matsumara
T, Kato K, Hu Z, Juteau JM, Vaillant A, Liang JT. The 57th Annual
Meeting of the American Association for the Study of Liver Diseases, 2006, Boston, USA).
The PS-ON are a promising new class of antiviral compounds that may have a
broad spectrum in all families of enveloped viruses.
Structural information of HCV
envelope glycoprotein E2 and CD81 was used to identify imidazole based
compounds that mimic an alpha helix in the LEL of CD81 and compete for the
binding of HCV E2 to CD81 expressed on target cells. These drugs bind HCV E2 in
a reversible manner and block HCV E2 interaction with CD81 while having no
effect on CD81 expression nor on CD81-interaction with physiological partner
molecules (106). However,
data of the effect of these drugs on HCVcc infection are not yet available. Recently,
SR-BI has been demonstrated to bind and internalize serum amyloid A (SAA), an
acute phase protein mainly produced in the liver and known to mediate
pro-inflammatory cellular responses (107, 108). SAA was
shown to inhibit HCV entry by interacting with the virus thereby reducing its
infectivity (109). Thus, SAA
analogues might present potent anti-HCV activity. In addition to small molecule
inhibitors, peptides that mimic conserved regions of HCV E2 interacting with
cell entry receptors may also provide an interesting approach to prevent HCV
infection but have weaknesses as drugs because they are not orally available
and expensive to produce.
Fusion inhibitors
Insights into the molecular
mechanisms of HCV fusion are just about to arise and molecules likely to
interfere with HCV penetration have not yet been described. As HCV enters the
host cell through endocytosis and requires low pH for delivery of HCV genome, agents preventing the acidification of endosomal
compartments, such as chloroquine, are able to prevent infection (72, 79). Potential targets for anti-fusion drugs might arise
in the next few years while insights into HCV fusion process are growing. Peptide-based
fusion inhibitors have already been established for the treatment of other viral
infections such as HIV infection. Enfuvirtide which blocks HIV fusion to host
cells is the first compound of this family approved for clinical use (110).
An analog of kisspeptin 10, and an antagonist of kisspeptin receptor (KISS1, GPR54) that inhibits kisspeptin-10 stimulation of inositol phosphate (IP) (IC50 = 7 nM) and release of gonadotrophin-releasing hormone (GnRH). Kisspeptin 234
ReplyDelete